Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity

Implications for the treatment of bone diseases

Nobuo Suzuki, Masanori Somei, Kei Ichiro Kitamura, Russel J Reiter, Atsuhiko Hattori

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The teleost scale is a calcified tissue that contains osteoclasts, osteoblasts, and bone matrix, all of which are similar to those found in mammalian membrane bone. Using the goldfish scale, we recently developed a new in vitro assay system and previously demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities in this assay system. In mammals, 2-bromomelatonin possesses a higher affinity for the melatonin receptor than does melatonin. Using a newly developed synthetic method, we synthesized 2-bromomelatonin, 2,4,6-tribromomelatonin and novel bromomelatonin derivatives (1-allyl-2,4,6-tribromomelatonin, 1-propargyl-2,4,6-tribromomelatonin, 1-benzyl-2,4,6-tribromomelatonin, and 2,4,6,7-tetrabromomelatonin) and then examined the effects of these chemicals on osteoclasts and osteoblasts. All bromomelatonin derivatives, as well as melatonin, had an inhibitory action on osteoclasts. In particular, 1-benzyl-2,4,6-tribromomelatonin (benzyl-tribromomelatonin) possessed a stronger activity than melatonin. At an in vitro concentration of 10-10 m, benzyl-tribromomelatonin still suppressed osteoclastic activity after 6 hr of incubation. In reference to osteoblasts, all bromomelatonin derivatives had a stimulatory action, although melatonin inhibited osteoblastic activity. In addition, estrogen receptor mRNA expression (an osteoblastic marker) was increased in benzyl-tribromomelatonin (10-7 m)-treated scales. Taken together, the present results strongly suggest that these novel melatonin derivatives have significant potential for use as beneficial drug for bone diseases such as osteoporosis.

Original languageEnglish (US)
Pages (from-to)326-334
Number of pages9
JournalJournal of Pineal Research
Volume44
Issue number3
DOIs
StatePublished - Apr 2008

Fingerprint

Bone Diseases
Melatonin
Osteoclasts
Osteoblasts
Melatonin Receptors
Goldfish
Bone Matrix
Estrogen Receptors
Osteoporosis
Mammals
benzyl-tribromomelatonin
Bone and Bones
Messenger RNA
Membranes
Pharmaceutical Preparations

Keywords

  • Bone diseases
  • Bromomelatonin derivatives
  • Goldfish
  • Osteoblasts
  • Osteoclasts
  • Scales

ASJC Scopus subject areas

  • Endocrinology

Cite this

Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity : Implications for the treatment of bone diseases. / Suzuki, Nobuo; Somei, Masanori; Kitamura, Kei Ichiro; Reiter, Russel J; Hattori, Atsuhiko.

In: Journal of Pineal Research, Vol. 44, No. 3, 04.2008, p. 326-334.

Research output: Contribution to journalArticle

@article{3fd743a26ba542e4bb70687f0621d89b,
title = "Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: Implications for the treatment of bone diseases",
abstract = "The teleost scale is a calcified tissue that contains osteoclasts, osteoblasts, and bone matrix, all of which are similar to those found in mammalian membrane bone. Using the goldfish scale, we recently developed a new in vitro assay system and previously demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities in this assay system. In mammals, 2-bromomelatonin possesses a higher affinity for the melatonin receptor than does melatonin. Using a newly developed synthetic method, we synthesized 2-bromomelatonin, 2,4,6-tribromomelatonin and novel bromomelatonin derivatives (1-allyl-2,4,6-tribromomelatonin, 1-propargyl-2,4,6-tribromomelatonin, 1-benzyl-2,4,6-tribromomelatonin, and 2,4,6,7-tetrabromomelatonin) and then examined the effects of these chemicals on osteoclasts and osteoblasts. All bromomelatonin derivatives, as well as melatonin, had an inhibitory action on osteoclasts. In particular, 1-benzyl-2,4,6-tribromomelatonin (benzyl-tribromomelatonin) possessed a stronger activity than melatonin. At an in vitro concentration of 10-10 m, benzyl-tribromomelatonin still suppressed osteoclastic activity after 6 hr of incubation. In reference to osteoblasts, all bromomelatonin derivatives had a stimulatory action, although melatonin inhibited osteoblastic activity. In addition, estrogen receptor mRNA expression (an osteoblastic marker) was increased in benzyl-tribromomelatonin (10-7 m)-treated scales. Taken together, the present results strongly suggest that these novel melatonin derivatives have significant potential for use as beneficial drug for bone diseases such as osteoporosis.",
keywords = "Bone diseases, Bromomelatonin derivatives, Goldfish, Osteoblasts, Osteoclasts, Scales",
author = "Nobuo Suzuki and Masanori Somei and Kitamura, {Kei Ichiro} and Reiter, {Russel J} and Atsuhiko Hattori",
year = "2008",
month = "4",
doi = "10.1111/j.1600-079X.2007.00533.x",
language = "English (US)",
volume = "44",
pages = "326--334",
journal = "Journal of Pineal Research",
issn = "0742-3098",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity

T2 - Implications for the treatment of bone diseases

AU - Suzuki, Nobuo

AU - Somei, Masanori

AU - Kitamura, Kei Ichiro

AU - Reiter, Russel J

AU - Hattori, Atsuhiko

PY - 2008/4

Y1 - 2008/4

N2 - The teleost scale is a calcified tissue that contains osteoclasts, osteoblasts, and bone matrix, all of which are similar to those found in mammalian membrane bone. Using the goldfish scale, we recently developed a new in vitro assay system and previously demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities in this assay system. In mammals, 2-bromomelatonin possesses a higher affinity for the melatonin receptor than does melatonin. Using a newly developed synthetic method, we synthesized 2-bromomelatonin, 2,4,6-tribromomelatonin and novel bromomelatonin derivatives (1-allyl-2,4,6-tribromomelatonin, 1-propargyl-2,4,6-tribromomelatonin, 1-benzyl-2,4,6-tribromomelatonin, and 2,4,6,7-tetrabromomelatonin) and then examined the effects of these chemicals on osteoclasts and osteoblasts. All bromomelatonin derivatives, as well as melatonin, had an inhibitory action on osteoclasts. In particular, 1-benzyl-2,4,6-tribromomelatonin (benzyl-tribromomelatonin) possessed a stronger activity than melatonin. At an in vitro concentration of 10-10 m, benzyl-tribromomelatonin still suppressed osteoclastic activity after 6 hr of incubation. In reference to osteoblasts, all bromomelatonin derivatives had a stimulatory action, although melatonin inhibited osteoblastic activity. In addition, estrogen receptor mRNA expression (an osteoblastic marker) was increased in benzyl-tribromomelatonin (10-7 m)-treated scales. Taken together, the present results strongly suggest that these novel melatonin derivatives have significant potential for use as beneficial drug for bone diseases such as osteoporosis.

AB - The teleost scale is a calcified tissue that contains osteoclasts, osteoblasts, and bone matrix, all of which are similar to those found in mammalian membrane bone. Using the goldfish scale, we recently developed a new in vitro assay system and previously demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities in this assay system. In mammals, 2-bromomelatonin possesses a higher affinity for the melatonin receptor than does melatonin. Using a newly developed synthetic method, we synthesized 2-bromomelatonin, 2,4,6-tribromomelatonin and novel bromomelatonin derivatives (1-allyl-2,4,6-tribromomelatonin, 1-propargyl-2,4,6-tribromomelatonin, 1-benzyl-2,4,6-tribromomelatonin, and 2,4,6,7-tetrabromomelatonin) and then examined the effects of these chemicals on osteoclasts and osteoblasts. All bromomelatonin derivatives, as well as melatonin, had an inhibitory action on osteoclasts. In particular, 1-benzyl-2,4,6-tribromomelatonin (benzyl-tribromomelatonin) possessed a stronger activity than melatonin. At an in vitro concentration of 10-10 m, benzyl-tribromomelatonin still suppressed osteoclastic activity after 6 hr of incubation. In reference to osteoblasts, all bromomelatonin derivatives had a stimulatory action, although melatonin inhibited osteoblastic activity. In addition, estrogen receptor mRNA expression (an osteoblastic marker) was increased in benzyl-tribromomelatonin (10-7 m)-treated scales. Taken together, the present results strongly suggest that these novel melatonin derivatives have significant potential for use as beneficial drug for bone diseases such as osteoporosis.

KW - Bone diseases

KW - Bromomelatonin derivatives

KW - Goldfish

KW - Osteoblasts

KW - Osteoclasts

KW - Scales

UR - http://www.scopus.com/inward/record.url?scp=40849131148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849131148&partnerID=8YFLogxK

U2 - 10.1111/j.1600-079X.2007.00533.x

DO - 10.1111/j.1600-079X.2007.00533.x

M3 - Article

VL - 44

SP - 326

EP - 334

JO - Journal of Pineal Research

JF - Journal of Pineal Research

SN - 0742-3098

IS - 3

ER -